Don t focus on herd immunity, vaccination should be comprehensive: COVID-19 panel expert Toggle share menu
Advertisement
Don t focus on herd immunity, vaccination should be comprehensive: COVID-19 panel expert
Associate Professor Lim Poh Lian, an infectious diseases outbreak expert, dressed in personal protective equipment. (Photo courtesy of A/Prof Lim)
28 Dec 2020 10:25AM) Share this content
Bookmark
SINGAPORE: Rather than aim for a certain percentage of the population to be inoculated to achieve COVID-19 herd immunity, Singapore should vaccinate as many people as possible.
In an interview with CNA, Associate Professor Lim Poh Lian, who is on the Expert Committee for COVID-19 Vaccination, said that it s a mistake to focus on percentages when it comes to COVID-19 vaccination.
FDA approves osimertinib for treatment of non-small cell lung cancer medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.
FDA approves first adjuvant treatment for patients with non-small cell lung cancer
Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.
Today s approval of Tagrisso demonstrates how additional research on therapies approved in later stages of cancer can eventually improve treatment options for patients in earlier stages. With this approval, patients may be treated with this targeted therapy in an earlier and potentially more curative stage of non-small cell lung cancer.
Richard Pazdur, M.D., Director, FDA s Oncology Center of Excellence and Acting Director, Office of Oncologic Diseases in the FDA s Center for Drug Evaluation and Research
On December 18, 2020, the Food and Drug Administration approved osimertinib (TAGRISSO, AstraZeneca Pharmaceuticals LP) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Efficacy was demonstrated in a randomized, double-blind, placebo-controlled trial (ADAURA, NCT02511106) in patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC who had complete tumor resection, with or without prior adjuvant chemotherapy. Eligible patients with resectable tumors (stage IB – IIIA) were required to have predominantly non-squamous histology and EGFR exon 19 deletions or exon 21 L858R mutations identified prospectively from tumor tissue in a central laboratory by the cobas® EGFR Mutation Test. A total of 682 patients were randomized (1:1) to receive osimertinib 80 mg orally once daily or placeb
December 18, 2020
Determining whether a vaccine is safe for certain groups of people needs to be guided by data from vaccine studies.
The Straits Times
SINGAPORE - There are some groups of people who should wait to receive a Covid-19 vaccine, including those with a history of severe allergic reactions, said a panel of experts on Thursday (Dec 17).
Serious allergies usually refer to people who, in response to a specific stimulus such as a bee sting or medication, experience swelling around the mouth, eyes or face, have difficulty breathing or experience a serious drop in blood pressure, said Associate Professor Lim Poh Lian, the director of the high-level isolation unit at the National Centre for Infectious Diseases.